Glucose: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain) and PBAC (Australia) recommended or restricted glucose, while PHARMAC (New Zealand) and SMC (Scotland) did not recommend it.
The file has been open for more than a decade: 22 years separate the first record, 5 Feb 2003 at HAS (France), from the most recent, 12 Feb 2025 at HAS (France).
TLV (Sweden) changed its position: recommended on 30 Jun 2003, not recommended by 16 Feb 2010.
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for glucose, 1 submission was never made — an outcome set by the company rather than the assessor.
4 distinct indication wordings are recorded for glucose by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 58 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess glucose, on 5 Feb 2003; CIPM (Spain) did not open a file until 15 Dec 2022 — an unusually long tail of 19.8 years between the earliest and latest system to look at it.
The record arrives in waves: 13 separate years each carry two or more decisions, spread across 18 years in total.
5 of the 7 agencies here assessed glucose more than once, HAS (France) most often at 44 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for glucose.
The full ledger for glucose reads 33 recommended, 15 other, 8 not recommended and 1 non-submission, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 12 Feb 2025 | Listing (Transparency Committee) | SMR substantial | source |
| CIPM (Spain) | 15 Dec 2022 | Indicación terapéutica autorizada: Deshidratación hipertónica: vómitos, diarrea, sudoración profusa, fístulas gastrointe… | financed by the SNS · art. 92 e | source |
| PHARMAC (New Zealand) | 23 May 2019 | Hypoglycemia | PTAC advice: No Formal Recommendation | source |
| PBAC (Australia) | 2016 | Diabetes | The PBAC recommended listing of Attest VivaChek Ino Blood Glucose Test Strips under the sa… | source |
| SMC (Scotland) | 8 Aug 2011 | For the relief of symptoms in mild to moderate osteoarthritis of the knee. | not recommended | source |
53 further decisions for glucose, across 6 agencies, are not shown here. They link to 24 further source documents.
Related molecules
- vosoritide — also decided by HAS in 2025Q1
- methotrexate — also decided by HAS in 2025Q1
- ribociclib — also decided by HAS in 2025Q1
- rozanolixizumab — also decided by HAS in 2025Q1
- spesolimab — also decided by HAS in 2025Q1
- beclometasone / formoterol — also decided by HAS in 2025Q1
Coverage: 58 decisions for glucose from 7 agencies, 2003 to 2025. Data to 7 Sep 2026. ATC class B05C — Blood substitutes and perfusion. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.